Transcript Chemokien_Short_Present 01 06

January 2006
Forward Looking Statements
Certain statements contained in this presentation, other than statements of fact
that are independently verifiable at the date hereof, may constitute forward looking statements. Such statements, based as they are on the current
expectations of management of Chemokine, inherently involve numerous risks
and uncertainties, known and unknown, many of which are beyond Chemokine's
control. Such risks include, but are not limited to, the impact of general
economic conditions, economic conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Chemokine
does business, stock market volatility, fluctuations in costs, and changes to the
competitive environment due to consolidation, as well as other risks included in
Chemokine's preliminary prospectus under the heading " risk factors", which you
are urged to read. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance on the forward-looking statements included in
this presentation . These statements speak only as update of the date they are
made and Chemokine is under no obligation to revise such statements as a
result of any event, circumstance or otherwise except in accordance with law.
1
COMPANY AT A GLANCE
• Biotechnology company with products
• OTCBB: CHKT
• Shares: 42 million
• 52 weeks: $0.8 – 1.30
• Market Cap. $45 million
• Well funded and Sufficient funds on hand for
Two lead drugs to the end of Phase II trials
• Also trades on Toronto: CTI
1
What are Chemokines?
Chemokines are a new and explosive drug
development field
Evidence:
1- November 2005 Pfizer buys chemokine program of
Incyte for $800 million
2- Summer 2004 Amgen buys First Chemokine company
(Tularik) for $1.2 billion
3- Summer 2003 Millennium Buys Leukocytes
(chemokine-based) for $600 million
3
Chemokines: New Class of Cytokines
Cytokines
Chemokines
Epogen, Neupogen,
Avonex, Intron
Fusion (first
chemokine-based
drug).
Roche/Trimeris
20B
$
1B
$
Same Market Potential
4
Product Pipeline
Drug
Stage of Development
Research
Lab Testing
Animal
Testing
Human
Phase I
CTCE9908
Cancer
CTCE0214
Immune System Booster
CTCE0324
Human
Phase II
Human
Phase III
Market
Vascular Disease
CTCEAnti-Infection
0422
CTCE0501
Stroke
5
Metastasisequalsdeath
Product # 1:
CTCE-9908
6
Cancer Relapses, due to Metastasis
•
Almost all cancer deaths are due to cancer metastasis
•
A new approach has taken by us which
Stops the spread of cancer through
Inhibition of cancer metastasis process
32
Cancer Relapse Due to Metastasis
2.
Lung
Cancer cells migrate to
tissue with a high SDF-1
concentration
Primary tumour
1.
Cancer cells detach
and migrate to
blood vessel
3.
Liver
Cancer cells accumulate
and form new tumour
Bone
7
CXCR4 – A Validated Target
> 2,000 publications on CXCR4
200 related to cancer
CXCR4
Role established in metastasis
of several types of cancer,
Muller et al, Nature, 2001
Many independent labs
working on CXCR4
Cancer cell
8
CTCE-9908 Targeting CXCR4
The only known natural
chemokine for CXCR4
SDF-1
CXCR4
An antagonist that
blocks SDF-1 binding to
CXCR4, preventing the
formation of metastastic
tumours
CTCE-9908
Cancer cell
9
CTCE-9908 Preclinical Findings
Average
65%
Response
Rate
Lung cancer
68%
Bone cancer
67%
Skin cancer
65%
Prostate cancer
61%
12
CTCE-9908 Phase I Results
No dose
limiting
toxicity
Volunteers
n = 24 (18 male, 6 female)
Single dose
Maximum dose tested 5 mg/kg
12
CTCE-9908 Next Step to Added Value
 Chemokine to start Phase Ib/II clinical trials in the Q1, 2006
 Expected results in Q4, 2006
14
Bloodequalslife
Product # 2:
CTCE-0214
16
Blood Cell System Disorders
Suppressed state
(Chemotherapy, AIDS, etc.)
Healthy state
Bone
marrow
Spleen
Rate of mobilization no longer fully
replenishes WBCs and platelets
Platelets
Blood vessel
Stem cells
White blood cells (WBC)
Fewer WBCs and platelets
results in infections/fatigue and
other medical complications 17
CTCE-0214 Targeting CXCR4
The only known natural
chemokine for CXCR4
SDF-1
• A CXCR4 agonist
• Mobilizes stem cells
from bone marrow
and spleen
CXCR4
• Assists in the
differentiation of stem
cells into white blood
cells and platelets
CTCE-0214
Stem cells
and
White Blood Cells
(WBC)
• Mobilizes WBCs
and platelets
18
CTCE-0214 Clinical Trial Phase I
Conducted in Tacoma/Seattle, Washington under US-IND
Enrolled 24 volunteer subjects
Randomized, double-blind, placebo controlled
Results:
The drug showed to be safe and well tolerated
Preliminary efficacy was observed
20
CTCE-0214 Clinical Phase I Efficacy
300%
Increase
in WBCs
Safety established –
No serious adverse events
Dose dependant
response at 6, 12 and
24 hours
Warrants advancing to
additional clinical trials
21
CTCE-0214 Market Potential
White blood cell products represent US$3 B
Projected to grow to US$4.5 B by 2008
Dominated by Neupogen® of Amgen
• Takes at least 4-5 days for response on average and up to 14 days
for full recovery
CTCE-0214 has fast action
• Potential to enhance production and infection fighting capacity of
white blood cells in all patients
• Potential to act synergistically with Neupogen®
22
CTCE-0214 Next Step to Value
• We have started the second Phase of clinical trials
Phase Ib/II in Dec. 2005
• The work is being conducted in Tacoma, Washington
• Results are expected in the Summer of 2006
23
Peripheral Arterial Disease
Product #3
CTCE-0324
26
Peripheral Arterial Disease (PAD)
Causes:
Diabetes
Obesity
Age
Atherosclerosis
Current Treatment:
Amputation
Physiotherapy
Exercise
Aspirin
10 million patients
in the USA
26
Our Drug Generates New Blood Vessels
Main Vasculature
After 2 Weeks
Control - Untreated
Neovascularization occurs
with CTCE-0324 compound
Market Potential: $10 Billion
27
Company Management and Advisors
Hassan Salari, PhD - Founder, President & CEO
Founding President and CEO Inflazyme Pharma
Former Professor of Medicine, UBC
Walter Korz - Vice President, Drug Development
Former Manager of clinical development Angiotech
Malcolm Moore, D. Phil. (Medical Advisor)
Professor Memorial Sloan Kettering Cancer Institute, NY
Co-discoverer of Neupogen for Amgen
Shahin Rafii, M.D. (Medical Advisor)
Howard Hughes Medical Institute Award
Recipient, Cornell Medical Center, NY
Edward Ball, M.D. (Medical Advisor)
Professor University of California San Diego
Co-founder Medarex, NJ
30
Comparables
Company
Stage
Market Cap.
Chemokine (CHKT)
Phase I/II
$45 million
Point Ther (POTP)
Oxigene (OXGN)
Phase II
Phase II
$100 million
$115 million
AnorMED (AOM)
Phase II
$130 million
Curis (CRIS)
Phase II
$215 million
Aastrom Bio (ASTM)
Phase II
$285 million
Stem Cells Inc (STEM)
Phase II
$325 million
30
Exit Strategy (Partnership / M&A)
• 2005 Pfizer and Incyte Pharmaceuticals. Incyte
finishes Phase II (IBD). Pfizer license the product
for $800 million
• 2004 Amgen and Tularik. Tularik finishes Phase II
(arthritis). Amgen buys Tularik for $1.2 Billion
• 2003 Millennium Pharmaceuticals and Leukocytes.
Leukocytes finishes Phase II (transplant).
Millennium buys leukocyte for $600 million
• Chemokine Therapeutics, 16 patents, lead in
cancer, blood disorder, vascular, 9-12 months away
from finishing Phase II >>>>>>>>>>> $$$
The Company in Review
• Biotechnology company with 5 products
– Two drugs in Phase II in 2006
– One drug entering IND in 2006
– Two products in animal studies
• 16 patents
• Licensing or M & A in the horizon
• Publicly Traded – OTCBB:
CHKT and TSX: CTI
• Visit our website: www.CHKT.com
2